Helena Yu, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the treatment landscape of EGFR exon 20 insertion (ex20ins)-mutated non–small cell lung cancer (NSCLC) and how the novel agent zipalertinib fills unmet needs. The current therapeutic landscape for EGFR exon20ins mutation-positive lung cancer highlights a distinct need for more convenient and patient-friendly treatment options. The delivery method contrasts with many other successful targeted therapies in lung cancer, which are often administered orally. To fully appreciate the significance of this research, one must understand the prevalence of EGFR mutations in lung cancer. EGFR-mutant lung cancer accounts for approximately 15% to 20% of all lung cancer cases diagnosed in the United States.